Proactive – Algernon Pharmaceuticals considers adding lung scarring for additional endpoint in Ifenprodil study
Algernon Pharmaceuticals (CSE: AGN- OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive to bring news that the Company is looking to add lung scarring as an additional endpoint in their Phase 2b/3 study of the repurposed drug Ifenprodil.
Mr. Moreau explains if the data can show that the dug reduces lung scarring, it would mean they can use Ifenprodil for treating lung damage due to Covid-19.
